Drugs / hLB-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04581785 | May 2021 → Jan 2023 | methylmalonic acidemia | LogicBio Therapeutics, Inc | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | hLB-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04581785 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “hLB-001 is a liver-targeted, recombinant engineered adeno-associated viral (rAAV) vector” NCT04581785 ↗ |
| Route | Intravenous | “hLB-001 via IV infusion” NCT04581785 ↗ |